EX-23.1 7 btai-20231231xex23d1.htm EX-23.1 Consent - Form 10-K or Form 8-K

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

​

We consent to the incorporation by reference in the following Registration Statements:

​

(1)Registration Statements (Form S-3 Nos. 333-265277, 333-275261 and 333-276488) of BioXcel Therapeutics, Inc., and

​

(2)Registration Statements (Form S-8 Nos. 333-235282, 333-238580, 333-266922 and 333-270652) pertaining to the 2017 Equity Incentive Plan and the 2020 Incentive Award Plan and 2020 Employee Stock Purchase Plan of BioXcel Therapeutics, Inc.

​

of our report dated March 22, 2024, with respect to the consolidated financial statements of BioXcel Therapeutics, Inc. included in this Annual Report (Form 10-K) of BioXcel Therapeutics, Inc. for the year ended December 31, 2023.

​

​

/s/ Ernst & Young, LLP

              ​

Stamford, Connecticut

​

March 22, 2024

​